Advertisement

Topics

DBV Technologies enrols first patient in Phase III peanut allergy trial

19:00 EDT 2 Aug 2017 | Net Resources International

French biopharmaceutical firm DBV Technologies has started patient enrolment in a Phase III EPITOPE clinical trial of Viaskin Peanut to treat peanut allergy in young children.

Original Article: DBV Technologies enrols first patient in Phase III peanut allergy trial

NEXT ARTICLE

More From BioPortfolio on "DBV Technologies enrols first patient in Phase III peanut allergy trial"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...